Migraine Care

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

magnesium citrate, Quantity: 928.22 mg (Equivalent: magnesium, Qty 150 mg); pyridoxine hydrochloride, Quantity: 15.19 mg (Equivalent: pyridoxine, Qty 12.5 mg); Tanacetum parthenium, Quantity: 40 mg (Equivalent: Tanacetum parthenium, Qty 280 mg; Equivalent: parthenolide, Qty 200 microgram); ubidecarenone, Quantity: 75 mg; calcium folinate, Quantity: 347.2 microgram (Equivalent: folinic acid, Qty 250 microgram); riboflavin, Quantity: 200 mg; cyanocobalamin, Quantity: 200 microgram

Disponibbli minn:

FIT-BioCeuticals Pty Ltd

INN (Isem Internazzjonali):

Calcium folinate,Cyanocobalamin,Magnesium citrate,pyridoxine hydrochloride,Riboflavin,Tanacetum parthenium,Ubidecarenone

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: croscarmellose sodium; chlorophyllin-copper complex; titanium dioxide; crospovidone; povidone; colloidal anhydrous silica; macrogol 8000; magnesium stearate; Carnauba Wax; hypromellose; microcrystalline cellulose

Rotta amministrattiva:

Oral

Indikazzjonijiet terapewtiċi:

Antioxidant/Reduce free radicals formed in the body ; Maintain/support energy production ; Aid/assist healthy red blood cell production ; Maintain/support red blood cell health ; Support healthy stress response in the body ; Helps reduce occurrence of mild migraines ; Decrease/reduce duration of mild migraine ; Maintain/support nerve conduction ; Aid/assist/helps synthesis of neurotransmitters ; Maintain/support nervous system function

Sommarju tal-prodott:

Visual Identification: ;

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2014-01-31